Biomarkers, immune monitoring, and novel technologies
760 Trough levels of ipilimumab in serum as a potential predictive biomarker of clinical outcomes for patients with advanced melanoma after treatment with ipilimumab
Share this article
Click the icon of the social media platform on which you would like to share this article.
Email this article to a friend
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.